Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials

Elisabet E. Manasanch, MD, Julia Wilkerson, BS, Liang Xiu, Sen Zhuang, MD, PhD, Susan Bates, MD, Wilfred Stein, PhD, Antonio T Fojo, MD, PhD

Blood (2011) 118 (21): 5113.

https://doi.org/10.1182/blood.V118.21.5113.5113

Published: 2011

Journal Articles

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L Allen, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, Ian D. Lewis, MD, Miles Prince, MD, MRACMA, FRACP, FRCPA, Sonali Smith, MD, Elaine S Jaffe, MD, Susan Bates, MD

Blood (2009) 114 (22): 1657.

https://doi.org/10.1182/blood.V114.22.1657.1657

Published: 2009

Journal Articles

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Sean Whittaker, MD, FRCP, Ellen J Kim, MD, Miles Prince, Marie France Demierre, MD, Cynthia Giver, Sagar Lonial, MD, Richard Piekarz, MD, PhD, Youn H Kim, MD, Jean Nichols, PhD, Darrell Nix, Ph.D., Susan Bates, MD

Blood (2009) 114 (22): 3701.

https://doi.org/10.1182/blood.V114.22.3701.3701

Published: 2009

Journal Articles

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Christopher Cabell, M.D., M.H.S., F.A.C.C., Susan Bates, MD, Richard Piekarz, MD, PhD, Sean Whittaker, MD, FRCP, Youn H Kim, MD, Michelle Currie, C. J Godfrey, Ph.D., Christopher Schoonmaker, Ph.D., Jean Nichols, PhD, Darrell Nix, Ph.D., Howard A. Burris, MD

Blood (2009) 114 (22): 3709.

https://doi.org/10.1182/blood.V114.22.3709.3709

Published: 2009

Journal Articles

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRACP, Mark Kirschbaum, MD, John P Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Elaine Jaffe, MD, Susan Bates, MD

Blood (2008) 112 (11): 1567.

https://doi.org/10.1182/blood.V112.11.1567.1567

Published: 2008

Journal Articles

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Susan Bates, MD, Richard Piekarz, MD, PhD, John Wright, MD, PhD, Robin Frye, RN, William Douglas Figg, Sr., PharmD, Steven L. Allen, MD, Michael Craig, MD, Larisa Geskin, MD, FAAD, Laura Hutchins, MD, David Joske, MBBS, FRCPA, FRAPC, Mark Kirschbaum, MD, John P. Leonard, MD, Miles Prince, MD, Craig B. Reeder, MD, Maryalice Stetler- Stevenson, MD, PhD, Alex Ling, MD, Jean Nichols, PhD

Blood (2008) 112 (11): 1568.

https://doi.org/10.1182/blood.V112.11.1568.1568

Published: 2008

Journal Articles

Efflux of the Tyrosine Kinase Inhibitors Imatinib and Nilotinib (AMN107) Is Mediated by ABCB1 (MDR1)-Type P-Glycoprotein.

Marius Dohse, Robert W. Robey, Cornelia Brendel, Susan Bates, Andreas Neubauer, Christian Scharenberg

Blood (2006) 108 (11): 1367.

https://doi.org/10.1182/blood.V108.11.1367.1367

Published: 2006

Journal Articles

Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells

Masaki Kitazono, Vemulkonda Koneti Rao, Rob Robey, Takashi Aikou, Susan Bates, Tito Fojo, Merrill E. Goldsmith

Blood (2002) 99 (6): 2248–2251.

https://doi.org/10.1182/blood.V99.6.2248

Published: 2002

Journal Articles

Efflux of Rhodamine From CD56 + Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833

Robert Robey, Susan Bakke, Wilfred Stein, Beverly Meadows, Thomas Litman, Sheela Patil, Tom Smith, Tito Fojo, Susan Bates

Blood (1999) 93 (1): 306–314.

https://doi.org/10.1182/blood.V93.1.306

Published: 1999

NARROW

Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor.

Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.

Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).

Final Clinical Results of a Phase 2 NCI Multicenter Study of Romidepsin in Recurrent Cutaneous T-Cell Lymphoma (Molecular Analyses Included).

Efflux of the Tyrosine Kinase Inhibitors Imatinib and Nilotinib (AMN107) Is Mediated by ABCB1 (MDR1)-Type P-Glycoprotein.

Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells

Efflux of Rhodamine From CD56 + Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only